TAVI Wars, Episode III. Troubling data for the Acurate neo2 in the regulatory trial just presented here at #TCT2024 (currently unpublished), with increased cardiac mortality (as had occurred with the first-generation valve in our SCOPE 2 trial) and stroke, with noninferiority not achieved for the primary outcome compared with other commercially available valves. The discussion seems somewhat detached because if I had just entered the main arena now, I would have thought the trial was positive. They are justifying this with the high rate of underexpanded valves and are strongly recommending post-dilation after implantation, if necessary. What happens now?
Comparison of different percutaneous revascularisation timing strategies in patients undergoing #TAVI
Read this new #EAPCI/PCR Journal Club review โ๏ธ๐ผ of an article selected in @EuroInterventio by @ABeneduceMD & Omar Alessandro Oliva:
https://t.co/N9EZtETNWH
#TAVR
Hybrid IVUS-OCT systems can overcome the limitations associated with each technology and integrate the advantages of both modalities. Recently, aย novel hybrid imaging system (PANOVISION) was approved for clinical use and tested in this noniferiority trial. https://t.co/jEH0Eva5gm
This study describes the characteristics and outcomes of TAVI patients with significant concomitant MR of different aetiologies. It demonstrates that increased MR severity at baseline contributes to worse outcomes following TAVI. https://t.co/QsHtpOB5gz
Successful use of an aspiration-fenestration technique in a patient with occlusive spontaneous coronary artery dissection due to extensive intramural haematoma. This technique could be a viable option in case of proximal failure to regain the true lumen. https://t.co/F5UCon9svE
Simply incredible to see the amount of details we are about to get in the #VHD field !!!! Easy to anticipate that we will know much more on #AS pts and #TAVR in the upcoming yearsโฆ.
In this trial of bifurcation PCI, the rates of malapposed and jailed struts around the bifurcation were not significantly different between POT with SD dilatation and conventional kissing balloon inflation, and clinical events at 1 year were low.#EIJBestOF https://t.co/KXD7cJ2W3Q
Caffeine is a competitive antagonist of adenosine, but no standardized guideline exists on caffeine abstinence prior to FFR. This study demonstrated a linear relationship between serum caffeine level and adenosine-induced FFR overestimation. #EIJBestOf https://t.co/r7m3J8AWU9
Happy to see at #PCRLV@CristinaAuri17 reporting the good 1-year result achieved in a pt with severe #mitral stenosis and high Wilkins score using our original #TEE#echofirst guided #PTMV technique. https://t.co/IuJUuqpiv0
Thanks @OptimaCTO Optimal PCI London for having us. Challenging live case from @emoryhealthcare 69 yo sp stroke surg TD EF 27%, with LAD, RCA and OM CTOs. @ProtectedPCI and antegrade LAD CTO PCI and retro for RCA. Will complete rev with OM CTO in 1 month. @wjn_md
Great case by @RinfretStephane for @OptimaCTO Double CTO PCI with Impella-support, EF 27%. Great demonstration how safe high complex PCI can be! @jcspratt
Really sad to read today the landmark editorial on the COAPT score from the late Michele Pighi: we will miss you!
https://t.co/h5C0fXHtbT
@JACCJournals
Very sad and unbelievable news today for our community. Great gentleman, elegant, kind, nice, excellent interventional Cardiologist and scientist. Ciao Michele RIP @sicigise@EAPCIPresident@PCRonline
How good the outcome of #PCI in pts with #LM can be today? 5.1 % TLF @ 1 yr achieved in the largest prospective study using last generation #DES offering wide size range. Also, impact of #imaging (#IVUS or #OCT) guidance is (once more) evident. Thanks to the ROLEX group!!
Hybrid Cardiac Imaging for the Invasive Cardiologist, by Romagnoli, Burzotta, Aurigemma and Trani, is the 6th chapter of our book Hybrid Cardiac Imaging for Clinical Decision-Making, by Nudi, Schillaci, Biondi-Zoccai and Iskandrian
https://t.co/kUQIigjlam